会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Fusion protein comprising a Caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
    • 包含胱天蛋白酶结构域和核激素受体结合结构域的融合蛋白及其方法和用途
    • US08530168B2
    • 2013-09-10
    • US12665680
    • 2008-06-20
    • Yuanyuan ChuRalf KuehnWolfgang Wurst
    • Yuanyuan ChuRalf KuehnWolfgang Wurst
    • G01N33/53C07H21/04C12P21/06C12N15/00C12N5/00C07K1/00
    • C12N9/6475C07K14/72C07K14/721C07K2319/00
    • The present invention relates to a fusion protein comprising a Caspase domain or a functionally active variant thereof and a ligand binding domain of a nuclear hormone receptor, a nucleic acid coding for the fusion protein, a vector or cell comprising the nucleic acid, a method of producing the fusion protein, a non-human transgenic animal containing the nucleic acid, the use of the fusion protein for ligand-mediated induction of apoptosis of a cell, or for studying the function of a cell, tissue and/or organ or the use of a transgenic organism for studying the function of a cell at various developmental stages or as a disease model, a method for inducing apoptosis of a cell expressing a fusion protein or for identifying a ligand, or a medicament comprising a fusion protein, the nucleic acid, the vector or the cell, particularly for the treatment of cancer or for or after transplantation, particularly as safety mechanism.
    • 本发明涉及包含胱天蛋白酶结构域或其功能活性变体和核激素受体的配体结合结构域,编码融合蛋白的核酸,包含核酸的载体或细胞的融合蛋白, 产生融合蛋白,含有核酸的非人转基因动物,融合蛋白用于配体介导的诱导细胞凋亡的用途,或用于研究细胞,组织和/或器官的功能或用途 用于研究各种发育阶段的细胞功能或作为疾病模型的转基因生物体,诱导表达融合蛋白或鉴定配体的细胞凋亡的方法或包含融合蛋白的药物,所述核酸 ,载体或细胞,特别是用于治疗癌症或移植后或移植后,特别是作为安全机制。
    • 6. 发明申请
    • VECTORS AND METHODS FOR GENERATING VECTOR-FREE INDUCED PLURIPOTENT STEM (IPS) CELLS USING SITE-SPECIFIC RECOMBINATION
    • US20110061118A1
    • 2011-03-10
    • US12933362
    • 2009-03-17
    • Ralf KühnWolfgang Wurst
    • Ralf KühnWolfgang Wurst
    • A01K67/02C07H21/04C12N15/63C12N5/10C12N15/79C12Q1/68C12Q1/02C12N5/071
    • C07K14/4702C12N5/0696C12N15/85C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2510/00C12N2800/30C12N2830/003C12N2840/206
    • The present invention relates to a DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem (iPS) cell; (ab) a promoter mediating the transcription of said coding sequence; and (ac) two sequence motifs that mediate excision of (aa) and/or (ab) from the DNA molecule, wherein one sequence motif is positioned 5′ and the other sequence motif is positioned 3′ of the sequence to be excised; (b) a second DNA sequence comprising a sequence motif that mediates site-specific integration of (a) into another DNA molecule. Further, the invention relates to DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem cell; and (ab) a promoter mediating the transcription of said coding sequence; (b) a second DNA sequence comprising: (ba) a sequence motif that mediates extrachromosomal self-replication of the DNA-molecule; and (bb) two sequence motifs that mediate excision of at least said sequence motif of (ba) from the second DNA sequence (b), wherein one sequence motif is located 5′ of (ba) and the other sequence motif 3′ of (ba). Also, the invention relates to a vector comprising the DNA molecule of the invention, a method for assembly of said vector and a somatic cell comprising said DNA molecule or said vector of the invention. Furthermore, the invention relates to methods to generate an induced pluripotent stem (iPS) cell, an induced pluripotent stem cell obtainable by said methods, to a kit comprising the DNA molecule of the invention, to a cell line or cell culture collection comprising the induced pluripotent stem cell of the invention, to the use of said cell or cell line as a research tool, to a method to generate a transgenic non-human animal and to a non-human animal generated by said method. Finally, the invention relates to a composition for gene therapy, regenerative medicine, cell therapy or drug screening.
    • 8. 发明申请
    • RECOMBINATION EFFICIENCY BY INHIBITION OF NHEJ DNA REPAIR
    • 通过抑制NHEJ DNA修复的重组效率
    • US20140304847A1
    • 2014-10-09
    • US14124106
    • 2012-06-06
    • Ralf KühnWolfgang Wurst
    • Ralf KühnWolfgang Wurst
    • C12N15/85
    • C12N15/85C12N15/1024C12N15/8509C12N15/907
    • The present invention relates to a method for modifying a target sequence in the genome of a mammalian cell, the method comprising the step of introducing into a mammalian cell: a. one or more compounds that introduce double-strand breaks in said target sequence; b. one or more DNA molecules comprising a donor DNA sequence to be incorporated by homologous recombination into the genomic DNA of said mammalian cell within said target sequence, wherein said donor DNA sequence is flanked upstream by a first flanking element and downstream by a second flanking element, wherein said first and second flanking element are different and wherein each of said first and second flanking sequence are homologous to a continuous DNA sequence on either side of the double-strand break introduced by said one or more compounds of a. within said target sequence in the genome of said mammalian cell; and c. one or more compounds that decrease the activity of the non-homologous end joining (NHEJ) DNA repair complex in said mammalian cell. Further, the invention relates to a method of producing a non-human mammal carrying a modified target sequence in its genome.
    • 本发明涉及一种用于修饰哺乳动物细胞基因组中靶序列的方法,所述方法包括引入哺乳动物细胞的步骤:a。 一种或多种在所述靶序列中引入双链断裂的化合物; b。 一个或多个DNA分子,其包含通过同源重组并入所述靶序列内的所述哺乳动物细胞的基因组DNA中的供体DNA序列,其中所述供体DNA序列在第一侧翼元件的上游侧和第二侧翼元件的下游, 其中所述第一和第二侧翼元件是不同的,并且其中所述第一和第二侧翼序列中的每一个与由所述一种或多种a的化合物引入的双链断裂的任一侧上的连续DNA序列同源。 在所述哺乳动物细胞的基因组中的所述靶序列内; 和c。 一种或多种降低所述哺乳动物细胞中非同源末端连接(NHEJ)DNA修复复合物的活性的化合物。 此外,本发明涉及在其基因组中生产携带修饰的靶序列的非人哺乳动物的方法。
    • 9. 发明申请
    • HOMOLOGOUS RECOMBINATION IN THE OOCYTE
    • 同卵生物的重组
    • US20120276537A1
    • 2012-11-01
    • US13504587
    • 2010-10-28
    • Ralf KühnWolfgang WurstMelanie Meyer
    • Ralf KühnWolfgang WurstMelanie Meyer
    • C12N15/90C12Q1/68C12N15/89
    • A01K67/0278A01K2217/072A01K2227/105A01K2267/01C12N9/22C12N15/8509C12N15/907
    • The present invention relates to a method of modifying a target sequence in the genome of a mammalian or avian oocyte by homologous recombination with a donor nucleic acid sequence, the method comprising the steps (a) introducing into the oocyte a zinc finger nuclease or a nucleic acid molecule encoding the zinc finger nuclease in expressible form, wherein the zinc finger nuclease specifically binds within the target sequence and introduces a double strand break within the target sequence; and (b) introducing a nucleic acid molecule into the oocyte, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence. The present invention further relates to a method of producing a non-human mammal or an avian carrying a modified target sequence in its genome.
    • 本发明涉及通过与供体核酸序列同源重组来修饰哺乳动物或禽类卵母细胞基因组中的靶序列的方法,所述方法包括以下步骤:(a)向卵母细胞中引入锌指核酸酶或核酸 编码锌指核酸酶的可分解形式的酸分子,其中所述锌指核酸酶在靶序列内特异性结合并在靶序列内引入双链断裂; 和(b)将核酸分子引入所述卵母细胞中,其中所述核酸分子包含供体核酸序列和与靶序列同源的区域。 本发明还涉及在其基因组中产生携带修饰的靶序列的非人哺乳动物或禽类的方法。
    • 10. 发明申请
    • MEANS AND METHODS FOR shRNA MEDIATED CONDITIONAL KNOCKDOWN OF GENES
    • US20100299771A1
    • 2010-11-25
    • US12678645
    • 2008-09-17
    • Ralf KühnWolfgang WurstPatricia Steuber-Buchberger
    • Ralf KühnWolfgang WurstPatricia Steuber-Buchberger
    • A01K67/027C12N15/63A01K67/00C12N5/10C12N15/09C12Q1/68
    • C12N15/111C12N2310/111C12N2310/14C12N2320/12C12N2320/50
    • The present invention relates to a combination of DNA segments comprising: (a) a first segment comprising in 5′ to 3′ or 3′ to 5′ order: (aa) a promoter; (ab) a first DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a first type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; (b) a second segment comprising in 5′ to 3′ or 3′ to 5′ order: (ba) a promoter; (bb) a second DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a second type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; wherein (i) said first type of recombinase recognition sequences are recognized and recombined by a recombinase but not recombined with said second type of recombinase recognition sequences; (ii) said second type of recombinase recognition sequences are recognized and recombined by the recombinase of (i) but not recombined with said first type of recombinase recognition sequences; and (iii) said DNA sequence of (ab) and (bb) is expressed under the control of said promoters of (aa) and (ba) upon removal of said transcriptional stop elements of (ab) and (bb) by the activity of a recombinase, resulting in transcription of said shRNA molecule in a cell. Further, the invention relates to a genetically engineered non-human animal and a method to produce said transgenic non-human animal. Also, the invention relates to a cell genetically engineered with the DNA molecule of the invention and a method of simultaneously knocking down two genes in a cell. Furthermore, envisaged is a method of identifying a combination of two target genes as a potential drug target and the use of the DNA molecule of the invention for the preparation of a composition for gene therapy.